 Once a safe and recommended dose level is determined, an Expanded Cohort of up to 60 patients with non-resectable cholangiocarcinoma 10 patients, breast carcinoma 10 patients, ovarian carcinoma 10 patients, endometrial carcinoma and carcinoma of the cervix 10 patients in total, at least five with endometrial carcinoma. Each group of 10 patients may enroll up to three patients who received at least 5-week gemcitabine treatment. The cohort will also include up to 20 patients with pancreatic carcinoma up to five out of 20 patients may have received at least 5-week gemcitabine treatment. 